Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash from Investing Activities: 2021-2025

Historic Cash from Investing Activities for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to -$45.0 million.

  • ARS Pharmaceuticals' Cash from Investing Activities fell 367.46% to -$45.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$69.1 million, marking a year-over-year decrease of 418.49%. This contributed to the annual value of -$106.1 million for FY2024, which is 21.70% down from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Cash from Investing Activities is -$45.0 million, which was down 192.61% from $48.6 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Cash from Investing Activities registered a high of $48.6 million during Q2 2025, and its lowest value of -$111.5 million during Q1 2023.
  • Its 3-year average for Cash from Investing Activities is -$14.6 million, with a median of -$8.5 million in 2024.
  • Within the past 5 years, the most significant YoY rise in ARS Pharmaceuticals' Cash from Investing Activities was 204,509.09% (2023), while the steepest drop was 531,071.43% (2023).
  • ARS Pharmaceuticals' Cash from Investing Activities (Quarterly) stood at $40.7 million in 2021, then slumped by 100.31% to -$126,000 in 2022, then spiked by 20,765.87% to $26.0 million in 2023, then slumped by 490.80% to -$101.8 million in 2024, then slumped by 367.46% to -$45.0 million in 2025.
  • Its last three reported values are -$45.0 million in Q3 2025, $48.6 million for Q2 2025, and $29.1 million during Q1 2025.